Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23130273 | 0.79 | CYP2C9 (0.49) | CYP2C9MAPTLMNANPSR1CYP1A2 | |
| SCHEMBL1491081 | 0.79 | POLB (0.58) | CYP2C9MAPTLMNAPTGS1PTGS2 | |
| SCHEMBL15553292 | 0.79 | MAPT (0.48) | CYP2C9MAPTLMNAPTGS1PTGS2 | |
| SCHEMBL31466259 | 0.79 | NPBWR1 (0.49) | MAPTNPBWR1MCHR1ALDH1A1KDM4E | |
| SCHEMBL5963747 | 0.79 | ALDH1A1 (0.47) | CYP2C9MAPTLMNANPBWR1MCHR1 | |
| SCHEMBL17910800 | 0.77 | MAPT (0.49) | CYP2C9MAPTLMNAPTGS1PTGS2 | |
| SCHEMBL17086615 | 0.76 | MAPT (0.52) | MAPTPTGS1PTGS2NPBWR1MCHR1 | |
| SCHEMBL12988815 | 0.76 | CYP2C9 (0.46) | CYP2C9MAPTLMNANPBWR1NPSR1 | |
| SCHEMBL18725081 | 0.76 | KDM5A (0.37) | CYP2C9MAPTLMNANPSR1ALDH1A1 | |
| SCHEMBL15299343 | 0.76 | NPC1 (0.41) | CYP2C9MAPTLMNAPTGS2NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2023-06-01 | — | — | US | disclosed |
| US-11584720-B2 | Photoredox-catalyzed direct C-H functionalization of arenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-02-21 | — | — | US | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10399947-B2 | Photoredox-catalyzed direct C—H functionalization of arenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180148414-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2018-05-31 | — | — | US | disclosed |
| US-20180148414-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2018-05-31 | — | — | US | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
| US-20110112111-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| WO-2008148840-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, DLAT | CYP2C9 185/4885MAPT 2039/4885LMNA 2272/4885 |
| US-11584720-B2 | Photoredox-catalyzed direct C-H functionalization of arenes | PPOX, AOC2, AOC3 | CYP2C9 230/4885MAPT 3005/4885LMNA 3847/4885 |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | CYP2C9 659/4885MAPT 2599/4885LMNA 3305/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | CYP2C9 1700/4885MAPT 3590/4885LMNA 3896/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | CYP2C9 1700/4885MAPT 3590/4885LMNA 3896/4885 |
| US-10399947-B2 | Photoredox-catalyzed direct C—H functionalization of arenes | PPOX, AOC2, AOC3 | CYP2C9 245/4885MAPT 2925/4885LMNA 3653/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | CYP2C9 617/4885MAPT 4829/4885LMNA 2443/4885 |
| US-20180148414-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | PPOX, AOC2, AOC3 | CYP2C9 230/4885MAPT 3005/4885LMNA 3847/4885 |
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | PPOX, AOC2, AOC3 | CYP2C9 230/4885MAPT 3005/4885LMNA 3847/4885 |
| US-20110112111-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | CYP2C9 659/4885MAPT 2599/4885LMNA 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.